Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)

Recruiting in Palo Alto (17 mi)

+7 other locations

Age: 18 - 65

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1

Waitlist Available

Sponsor: Cellectis S.A.

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial is testing a new treatment called UCARTCS1A, which uses modified immune cells to target and kill cancer cells. It is aimed at patients with multiple myeloma that has come back or didn't respond to other treatments. The goal is to see if this treatment is safe and effective. UCARTCS1A is a type of CAR-T cell therapy, which is a promising approach in treating multiple myeloma by using modified immune cells to target cancer cells.

Eligibility Criteria

Inclusion Criteria

Eastern Cooperative Oncology Group Performance Status of 0 or 1.

Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within the screening period.

You have not been treated before with experimental gene targeting CS1 or chimeric antigen receptor therapy targeting CS1.

See 4 more

Exclusion Criteria

Previous treatment with investigational gene therapy targeting CS1 or chimeric antigen receptor therapy targeting CS1.

Any cellular therapy (other than autologous or allogenic HSCT) within 60 days prior to enrollment.

Any known active or uncontrolled infection.

See 4 more